This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
WORCESTER, Mass., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today it has initiated an integrated Social Media campaign across its corporate website (
www.generex.com ) as well as its e-commerce websites for its various consumer diet, glucose raising and energy products, including Glucose RapidSpray™ (
www.GlucoseRapidSpray.com ), Crave-NX™ Diet Spray (
www.CraveNx.com ), BaBoom!™ Energy Spray (
www.BaBoomEnergySpray.com ) and Glucose RapidSpray™ for Pets™ (
www.GlucoseRapidSprayPets.com ). Through Facebook, Twitter and various other online community destinations, these social media campaigns serve to increase brand awareness, build online community engagement and enhance long-term customer loyalty via relevant content postings and on-demand conversations.
"We are excited about utilizing the social media campaign to introduce and communicate about our products and platforms within the vast online media landscape", said Rose C. Perri, Generex's Chief Operating Officer. "We consider this type of service as having a growing role in the future of patient, customer and investor communications."
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at
www.generex.com or the Antigen Express website at
The Generex Biotechnology Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3831Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the
Private Securities Litigation Reform Act.
CONTACT: American Capital Ventures, Inc.
Investor Relations Contact:
Beckerman Public Relations